(Q37856044)

24 August 2017

1 reference

title

Current status of experimental therapeutics for head and neck cancer (English)

1 reference

24 August 2017

Juna Lee

1

1 reference

24 August 2017

Chulso Moon

series ordinal

2

1 reference

24 August 2017

publication date

22 March 2011

1 reference

Experimental Biology and Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

236

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

375-389

1 reference

Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Molecular pathogenesis of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Panitumumab a novel drug in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Photodynamic therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Photodynamic therapy of head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Recent advances in surgery for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Photodynamic therapy for head and neck dysplasia and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Ultrasound-guided photodynamic therapy for deep seated pathologies: prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: phantom and volunteer experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Head and neck cancer--Part 1: Epidemiology, presentation, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Habitual risk factors for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

In vivo expansion of gene-modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010354

21 January 2018

Identifiers

DOI

10.1258/EBM.2010.010354

1 reference

24 August 2017

1 reference